FDA to authorize the use of the Pfizer COVID-19 vaccine for those ages 12 to 15 as early as next week, The New York Times reports
- The FDA is reportedly set to OK the
PfizerCOVID-19 vaccine for 12- to 15-year-olds by next week.
- Pfizer said in March that its vaccine was highly effective in a trial of over 2,000 adolescents.
- Nearly 150 million Americans had gotten at least one dose of a vaccine as of May 3, CDC data showed.
Following FDA authorization, an advisory panel from the Centers for Disease Control and Prevention will review data and results from clinical trials to draft recommendations on the use of the vaccine for that age group, according to The Times' report.Pfizer announced in March that its vaccine was highly effective in a trial of more than 2,000 adolescents and that the vaccine was "well tolerated" among those ages 12 to 15. Pfizer said the side effects of the vaccine experienced by that age group were similar to those of 16- to 25-year-olds.
Pfizer CEO Albert Bourla said in a statement in March that the company shared the "urgency to expand the authorization of our vaccine to use in younger populations." He said he hoped the clinical-trial data would prompt officials to start vaccinating the age group "before the start of the next school year."An FDA spokeswoman declined to comment to The Times on the agency's timeline of authorizing the vaccine for adolescents.
"We can assure the public that we are working to review this request as quickly and transparently as possible," the spokeswoman told The Times.Nearly 150 million Americans had received at least one dose of a
- CBSE class 10 results likely to be delayed as marks submission deadline for schools extended till June 30
- Maharashtra to consider staggered reopening depending on the COVID-19 cases in the state
- Indian government drops plasma therapy from guidelines for COVID-19 management
- A super hit IPO from 2020 has finally doubled investors' money